+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer

Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer

Cancer Letters 168(1): 31-36, July 10

The human androgen receptor (AR) gene contains a highly polymorphic CAG repeat in exon 1 that is inversely correlated with AR transcriptional activity in vitro. Several studies have shown that fewer CAG repeats are associated with an increased risk as well as more aggressive forms of prostate cancer. More recently, AR allele length was also inversely correlated with the histological grade of breast cancer, but no association was found between the AR-CAG polymorphism and the risk of either breast or ovary cancer. On the contrary, it was proposed that a longer CAG repeat sequence might be associated with an increased risk of breast cancer in BRCA1 mutation carriers, thus suggesting a different role of the AR-CAG polymorphism in sporadic and inherited breast cancers. With the intent of better understanding the role of the AR-CAG polymorphism as a cancer risk modifier, we defined the AR genotype of 151 patients (101 with breast and 50 with ovary cancer) belonging to high-risk breast/ovary cancer families. No difference in CAG repeat length was found between either breast and ovary cancer patients or age at diagnosis of both tumors. These results were also confirmed in a sub-group of 47 breast cancer cases, that either carried a BRCA gene mutation (11 cases) or were identified by very stringent operational criteria as hereditary breast cancers. Even though a substantially larger sample size would be required to reach conclusive evidence, our findings suggest that the AR-CAG polymorphism does not act as a modifier of tumor onset or tumor phenotype in breast/ovarian cancer families.

(PDF emailed within 0-6 h: $19.90)

Accession: 010906174

Download citation: RISBibTeXText

PMID: 11368874

DOI: 10.1016/s0304-3835(01)00473-6

Related references

Lack of association between the aryl hydrocarbon receptor rs2066853 polymorphism and breast cancer: A meta-analysis on Ahr polymorphism and breast cancer. Genetics and Molecular Research 14(4): 16162-8, 2016

Association of androgen receptor CAG repeat polymorphism and risk of epithelial ovarian cancer. Gene 575(2 Pt 3): 743-746, 2016

Analysis of the androgen receptor exon 1 trinucleotide repeat in familial breast/ovarian cancer cases. Tumori 86(4 Suppl 1): 22, July-August, 2000

Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer. Familial Cancer 12(4): 691-698, 2014

Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment 124(3): 815-820, 2011

Lack of Association between rs2067474 Polymorphism in Histamine Receptor H2 Gene and Breast Cancer in Chinese Han Population. Thescientificworldjournal 2015: 545292-545292, 2016

No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. British Journal of Cancer 75(9): 1398-1399, 1997

Lack of association between insulin receptor substrate2 rs1805097 polymorphism and the risk of colorectal and breast cancer: a meta-analysis. Plos One 9(1): E86911-E86911, 2014

Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 12(8): 597-603, 2002

Lack of association between vitamin D receptor gene BsmI polymorphism and breast cancer risk: an updated meta-analysis involving 23,020 subjects. Tumour Biology 35(3): 2087-2093, 2014

Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide. European Journal of Clinical Pharmacology 68(4): 371-377, 2012

Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian population. International Journal of Biological Markers 19(2): 160-163, 2004

Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility. Tumour Biology 35(4): 3385-3389, 2014

A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 29(10): 1963-1966, 2008